TriangleNCT02064387 · OUTCOME
Ctrough of GSK2857916 Following IV Dose in Participants With NHL-Part 2
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- Nanograms per milliliter
- Interval / dispersion
- Standard Deviation
- Time frame
- Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 3)
What was measured
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Analysis population: Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Groups in this outcome
Part 2: GSK2857916 3.40 mg/kg (NHL)
Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days).
| Group | Source count |
|---|---|
| Part 2: GSK2857916 3.40 mg/kg (NHL) | 5 |
Reported measurements
Cycle 1 Day 1, n=5
| Group | Source count |
|---|---|
| Part 2: GSK2857916 3.40 mg/kg (NHL) | 5 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 2: GSK2857916 3.40 mg/kg (NHL) | 0.0 | 0.00 | Not reported | Not reported | Not reported |
Cycle 2 Day 1, n=4
| Group | Source count |
|---|---|
| Part 2: GSK2857916 3.40 mg/kg (NHL) | 4 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 2: GSK2857916 3.40 mg/kg (NHL) | 3761.8 | 2225.57 | Not reported | Not reported | Not reported |
Cycle 3 Day 1, n=1
| Group | Source count |
|---|---|
| Part 2: GSK2857916 3.40 mg/kg (NHL) | 1 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 2: GSK2857916 3.40 mg/kg (NHL) | 8401.0 | NA | Not reported | Not reported | NA indicates that standard deviation could not be calculated for a single participant. |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 0.00
- value
- 0.0
- denoms
- counts
- group Id
- OG000
- value
- 5
- units
- Participants
- title
- Cycle 1 Day 1, n=5
- categories
- measurements
- group Id
- OG000
- spread
- 2225.57
- value
- 3761.8
- denoms
- counts
- group Id
- OG000
- value
- 4
- units
- Participants
- title
- Cycle 2 Day 1, n=4
- categories
- measurements
- comment
- NA indicates that standard deviation could not be calculated for a single participant.
- group Id
- OG000
- spread
- NA
- value
- 8401.0
- denoms
- counts
- group Id
- OG000
- value
- 1
- units
- Participants
- title
- Cycle 3 Day 1, n=1
- denoms
- counts
- group Id
- OG000
- value
- 5
- units
- Participants
- description
- Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
- dispersion Type
- Standard Deviation
- groups
- description
- Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days).
- id
- OG000
- title
- Part 2: GSK2857916 3.40 mg/kg (NHL)
- param Type
- MEAN
- population Description
- Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
- reporting Status
- POSTED
- time Frame
- Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 3)
- title
- Ctrough of GSK2857916 Following IV Dose in Participants With NHL-Part 2
- type
- SECONDARY
- unit Of Measure
- Nanograms per milliliter
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice